Bal Pharma balance sheet

As of Mar 2026

Total assets: ₹376cr+11.9% on Mar 2025
Shareholders' equity: ₹82.3cr+6.3% on Mar 2025
Total debt: ₹160cr+6.1% on Mar 2025
Cash and investments: ₹4.4cr+3.9% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	76.8	71.0	61.6	62.2
	7.4	2.8	0.5	0.0
	3.8	3.8	3.8	3.8
	13.4	12.0	11.4	10.5
	0.0	0.0	0.1	0.1
	8.1	7.1	2.7	3.5
	8.1	7.1	2.8	3.6
	0.8	0.4	2.4	2.2
	3.0	3.7	2.9	2.8
	113	101	85.4	85.0
	116	103	87.8	98.0
	2.1	2.5	6.8	0.0
	93.6	92.4	99.6	94.0
	2.3	1.8	4.2	1.5
	1.2	6.3	9.1	6.1
	0.0	1.1	1.4	1.0
	6.5	1.3	1.0	1.5
	106	105	122	104
	40.0	25.5	25.0	26.0
	262	235	235	228
	376	336	320	313
Equity
	15.9	15.9	15.8	15.7
	66.3	61.5	53.5	48.1
	82.2	77.4	69.3	63.8
	0.0	−0.0	−0.0	−0.1
	82.3	77.4	69.3	63.7
Liabilities
	31.9	31.4	36.4	30.5
	6.0	1.7	1.8	1.7
	37.9	33.1	38.2	32.2
	6.2	5.6	5.1	5.1
	0.0	0.0	4.0	2.9
	44.1	38.8	47.2	40.1
	128	119	103	100
	89.0	81.7	78.3	78.9
	24.6	10.7	9.3	9.2
	241	211	191	189
	0.8	1.2	0.9	0.6
	0.0	0.0	2.2	2.4
	7.2	6.9	9.8	17.7
	249	220	204	209
	293	258	251	249
	376	336	320	313
Assets — additional as-filed lines
	0.1	1.0	0.1	0.1
Trade payables — MSME split
	0.4	0.0	—	—
	88.6	81.7	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹86.17

Bal Pharma Limited

· Pharma & Health

₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹137 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	62.2	61.6	71.0	76.8	76.8
+ Capital Work-in-Progress	0.0	0.5	2.8	7.4	7.4
+ Goodwill	3.8	3.8	3.8	3.8	3.8
+ Other Intangibles	10.5	11.4	12.0	13.4	13.4
+ Long-term Loans	0.1	0.1	0.0	0.0	0.0
+ Other Non-current Financial Assets	3.5	2.7	7.1	8.1	8.1
Non-current Financial Assets	3.6	2.8	7.1	8.1	8.1
+ Deferred Tax Assets	2.2	2.4	0.4	0.8	0.8
+ Other Non-current Assets	2.8	2.9	3.7	3.0	3.0
Total Non-current Assets	85.0	85.4	100.8	113.3	113.3
Current Assets
+ Inventories	98.0	87.8	103.0	116.4	116.4
+ Current Investments	0.0	6.8	2.5	2.1	2.1
+ Trade Receivables	94.0	99.6	92.4	93.6	93.6
+ Cash & Cash Equivalents	1.5	4.2	1.8	2.3	2.3
+ Other Bank Balances	6.1	9.1	6.3	1.2	1.2
+ Short-term Loans	1.0	1.4	1.1	0.0	0.0
+ Other Current Financial Assets	1.5	1.0	1.3	6.5	6.5
Current Financial Assets	104.0	122.1	105.4	105.7	105.7
+ Other Current Assets	26.0	25.0	25.5	40.0	40.0
Total Current Assets	228.2	235.0	234.9	262.2	262.2
Total Assets	313.2	320.4	335.7	375.5	375.5
Equity
+ Equity Share Capital	15.7	15.8	15.9	15.9	15.9
+ Other Equity / Reserves	48.1	53.5	61.5	66.3	66.3
Equity — Owners of Parent	63.8	69.3	77.4	82.2	82.2
+ Minority Interest	-0.1	-0.0	-0.0	0.0	0.0
Total Equity	63.7	69.3	77.4	82.3	82.3
Liabilities
+ Borrowings — Non-current	30.5	36.4	31.4	31.9	31.9
+ Other Non-current Financial Liab	1.7	1.8	1.7	6.0	6.0
Non-current Financial Liabilities	32.2	38.2	33.1	37.9	37.9
+ Provisions — Non-current	5.1	5.1	5.6	6.2	6.2
+ Deferred Tax Liabilities	2.9	4.0	0.0	0.0	0.0
Non-current Liabilities	40.1	47.2	38.8	44.1	44.1
+ Borrowings — Current	100.5	103.3	119.0	127.6	127.6
+ Trade Payables	78.9	78.3	81.7	89.0	89.0
+ Other Current Financial Liab	9.2	9.3	10.7	24.6	24.6
Current Financial Liabilities	188.6	190.9	211.4	241.2	241.2
+ Provisions — Current	0.6	0.9	1.2	0.8	0.8
+ Current Tax Liabilities	2.4	2.2	0.0	0.0	0.0
+ Other Current Liabilities	17.7	9.8	6.9	7.2	7.2
Current Liabilities	209.3	203.9	219.5	249.2	249.2
Total Liabilities	249.5	251.1	258.3	293.3	293.3
Total Equity & Liabilities	313.2	320.4	335.7	375.5	375.5
Assets — additional as-filed lines
+ Current Tax Assets	0.1	0.1	1.0	0.1	0.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	0.0	0.4	0.4
+ Dues to Other Creditors — Current	—	—	81.7	88.6	88.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.